Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by Giuseppe Mancia and Guido Grassi.
Giuseppe Mancia
Connection Strength
17.573
Guido Grassi
  1. Sympathetic Neural Overdrive in the Obese and Overweight State. Hypertension. 2019 08; 74(2):349-358.
    View in: PubMed
    Score: 0.828
  2. Masked Uncontrolled Hypertension. Hypertension. 2019 01; 73(1):39-41.
    View in: PubMed
    Score: 0.802
  3. Monographic issue of pharmacological research on hypertension. Pharmacol Res. 2018 08; 134:221-222.
    View in: PubMed
    Score: 0.774
  4. Sympathetic Nerve Traffic Activation in Essential Hypertension and Its Correlates: Systematic Reviews and Meta-Analyses. Hypertension. 2018 08; 72(2):483-491.
    View in: PubMed
    Score: 0.773
  5. Blood pressure targets in type 2 diabetes. Evidence against or in favour of an aggressive approach. Diabetologia. 2018 Mar; 61(3):517-525.
    View in: PubMed
    Score: 0.752
  6. 'Keep an eye' on the heart: retinal microcirculation disarray in congestive heart failure. Eur Heart J. 2018 01 01; 39(1):57-59.
    View in: PubMed
    Score: 0.749
  7. Cardiovascular Risk Associated With White-Coat Hypertension: Pro Side of the Argument. Hypertension. 2017 10; 70(4):668-675.
    View in: PubMed
    Score: 0.731
  8. Quarter Dose Combination Therapy: Good News for Blood Pressure Control. Hypertension. 2017 07; 70(1):32-34.
    View in: PubMed
    Score: 0.719
  9. Hypertension: Quarter dose quadpill combinations: a new therapeutic approach. Nat Rev Nephrol. 2017 05; 13(5):266-267.
    View in: PubMed
    Score: 0.711
  10. Multicenter Randomized Double-Blind Comparison of Nebivolol plus HCTZ and Irbesartan plus HCTZ in the Treatment of Isolated Systolic Hypertension in Elderly Patients: Results of the NEHIS Study. Adv Ther. 2017 01; 33(12):2173-2187.
    View in: PubMed
    Score: 0.689
  11. Total cardiovascular risk, blood pressure variability and adrenergic overdrive in hypertension: evidence, mechanisms and clinical implications. Curr Hypertens Rep. 2012 Aug; 14(4):333-8.
    View in: PubMed
    Score: 0.514
  12. The sympathetic nervous system and new nonpharmacologic approaches to treating hypertension: a focus on renal denervation. Can J Cardiol. 2012 May; 28(3):311-7.
    View in: PubMed
    Score: 0.495
  13. Heart rate as a sympathetic marker during acute adrenergic challenge. J Hypertens. 2008 Jan; 26(1):70-5.
    View in: PubMed
    Score: 0.374
  14. Obstructive sleep apnea-dependent and -independent adrenergic activation in obesity. Hypertension. 2005 Aug; 46(2):321-5.
    View in: PubMed
    Score: 0.314
  15. Coronavirus disease 2019 and cardiovascular complications: focused clinical review. J Hypertens. 2021 07 01; 39(7):1282-1292.
    View in: PubMed
    Score: 0.238
  16. COVID-19 and arterial hypertension: Hypothesis or evidence? J Clin Hypertens (Greenwich). 2020 07; 22(7):1120-1126.
    View in: PubMed
    Score: 0.223
  17. COVID-19, hypertension and cardiovascular diseases: Should we change the therapy? Pharmacol Res. 2020 08; 158:104906.
    View in: PubMed
    Score: 0.220
  18. Extreme dipping: is the cardiovascular risk increased? An unsolved issue. J Hypertens. 2019 10; 37(10):1917-1926.
    View in: PubMed
    Score: 0.211
  19. Blood Pressure Non-Dipping and Obstructive Sleep Apnea Syndrome: A Meta-Analysis. J Clin Med. 2019 Sep 02; 8(9).
    View in: PubMed
    Score: 0.210
  20. Sympathetic neural overdrive in congestive heart failure and its correlates: systematic reviews and meta-analysis. J Hypertens. 2019 09; 37(9):1746-1756.
    View in: PubMed
    Score: 0.210
  21. Sympathetic Nerve Traffic and Arterial Baroreflex Function in Apparent Drug-Resistant Hypertension. Hypertension. 2019 10; 74(4):903-909.
    View in: PubMed
    Score: 0.209
  22. Resistant Hypertension Management: Comparison of the 2017 American and 2018 European High Blood Pressure Guidelines. Curr Hypertens Rep. 2019 07 18; 21(9):67.
    View in: PubMed
    Score: 0.208
  23. Response to: Myocardial fibrosis and arrhythmogenesis in elite athletes. Clin Cardiol. 2019 Jul 04.
    View in: PubMed
    Score: 0.208
  24. High-normal blood pressure and abnormal left ventricular geometric patterns: a meta-analysis. J Hypertens. 2019 07; 37(7):1312-1319.
    View in: PubMed
    Score: 0.208
  25. Incident Left Ventricular Hypertrophy in Masked Hypertension. Hypertension. 2019 07; 74(1):56-62.
    View in: PubMed
    Score: 0.206
  26. Serum uric acid and resistance to antihypertensive treatment: data from the European Lacidipine Study on Atherosclerosis. J Hypertens. 2019 04; 37(4):844-850.
    View in: PubMed
    Score: 0.204
  27. Left atrial volume in elite athletes: A meta-analysis of echocardiographic studies. Scand J Med Sci Sports. 2019 Jul; 29(7):922-932.
    View in: PubMed
    Score: 0.204
  28. High Normal Blood Pressure and Left Ventricular Hypertrophy Echocardiographic Findings From the PAMELA Population. Hypertension. 2019 03; 73(3):612-619.
    View in: PubMed
    Score: 0.203
  29. Relationships between residual blood pressure variability and cognitive function in the general population of the PAMELA study. J Clin Hypertens (Greenwich). 2019 01; 21(1):39-45.
    View in: PubMed
    Score: 0.199
  30. Pre-hypertension and subclinical carotid damage: a meta-analysis. J Hum Hypertens. 2019 01; 33(1):34-40.
    View in: PubMed
    Score: 0.197
  31. Risk of new-onset metabolic syndrome associated with white-coat and masked hypertension: data from a general population. J Hypertens. 2018 09; 36(9):1833-1839.
    View in: PubMed
    Score: 0.196
  32. Big Data and Blood Pressure Control: Insights from the PAMELA and BP-CARE Study Cohorts. Curr Hypertens Rep. 2018 07 26; 20(10):82.
    View in: PubMed
    Score: 0.195
  33. Sympathetic Nervous System, Sleep, and Hypertension. Curr Hypertens Rep. 2018 07 06; 20(9):74.
    View in: PubMed
    Score: 0.194
  34. White-Coat Hypertension: the Neglected Subgroup in Hypertension. Korean Circ J. 2018 Jul; 48(7):552-564.
    View in: PubMed
    Score: 0.194
  35. Uric acid and risk of new-onset metabolic syndrome, impaired fasting glucose and diabetes mellitus in a general Italian population: data from the Pressioni Arteriose Monitorate E Loro Associazioni study. J Hypertens. 2018 07; 36(7):1492-1498.
    View in: PubMed
    Score: 0.194
  36. Pre-hypertension and subclinical cardiac damage: A meta-analysis of echocardiographic studies. Int J Cardiol. 2018 Nov 01; 270:302-308.
    View in: PubMed
    Score: 0.193
  37. Night-time heart rate nondipping: clinical and prognostic significance in the general population. J Hypertens. 2018 06; 36(6):1311-1317.
    View in: PubMed
    Score: 0.193
  38. Sympathetic and baroreflex abnormalities in the uncomplicated prediabetic state. J Hypertens. 2018 05; 36(5):1195-1200.
    View in: PubMed
    Score: 0.191
  39. In Memoriam: Alberto Zanchetti (Parma July 27, 1926 - Milan March 24, 2018). J Clin Hypertens (Greenwich). 2018 05; 20(5):826-828.
    View in: PubMed
    Score: 0.191
  40. The importance of pulse pressure on cardiovascular risk and total mortality in the general population: Is sex relevant? J Clin Hypertens (Greenwich). 2018 06; 20(6):1001-1007.
    View in: PubMed
    Score: 0.191
  41. Carotid intima-media thickness and anti-hypertensive treatment: Focus on angiotensin II receptor blockers. Pharmacol Res. 2018 03; 129:20-26.
    View in: PubMed
    Score: 0.188
  42. Metabolic syndrome and subclinical carotid damage: a meta-analysis from population-based studies. J Hypertens. 2018 01; 36(1):23-30.
    View in: PubMed
    Score: 0.187
  43. Renal artery stenosis and left ventricular hypertrophy: an updated review and meta-analysis of echocardiographic studies. J Hypertens. 2017 12; 35(12):2339-2345.
    View in: PubMed
    Score: 0.186
  44. Association of metabolic syndrome with carotid thickening and plaque in the general population: A meta-analysis. J Clin Hypertens (Greenwich). 2018 01; 20(1):4-10.
    View in: PubMed
    Score: 0.186
  45. Restoration of normal sympathetic neural function in heart failure following baroreflex activation therapy: final 43-month study report. J Hypertens. 2017 12; 35(12):2532-2536.
    View in: PubMed
    Score: 0.186
  46. Long-term changes in left ventricular mass echocardiographic findings from a general population. J Hypertens. 2017 11; 35(11):2303-2309.
    View in: PubMed
    Score: 0.185
  47. Treatment of hypertension: The ESH/ESC guidelines recommendations. Pharmacol Res. 2018 02; 128:315-321.
    View in: PubMed
    Score: 0.185
  48. Reliability of heart rate as neuroadrenergic marker in the metabolic syndrome. J Hypertens. 2017 08; 35(8):1685-1690.
    View in: PubMed
    Score: 0.182
  49. Clinical and prognostic significance of a reverse dipping pattern on ambulatory monitoring: An updated review. J Clin Hypertens (Greenwich). 2017 Jul; 19(7):713-721.
    View in: PubMed
    Score: 0.181
  50. Long-term Saxagliptin Treatment Improves Endothelial Function but not Pulse Wave Velocity and Intima-Media Thickness in Type 2 Diabetic Patients. High Blood Press Cardiovasc Prev. 2017 Dec; 24(4):393-400.
    View in: PubMed
    Score: 0.180
  51. Uric Acid and New Onset Left Ventricular Hypertrophy: Findings From the PAMELA Population. Am J Hypertens. 2017 Mar 01; 30(3):279-285.
    View in: PubMed
    Score: 0.177
  52. Prognostic significance of left atrial enlargement in a general population: results of the PAMELA study. Hypertension. 2014 Dec; 64(6):1205-11.
    View in: PubMed
    Score: 0.149
  53. Long-term sympathoinhibitory effects of surgically induced weight loss in severe obese patients. Hypertension. 2014 Aug; 64(2):431-7.
    View in: PubMed
    Score: 0.146
  54. Comparison of echotracking and magnetic resonance assessment of abdominal aorta distensibility and relationships with pulse wave velocity. Ultrasound Med Biol. 2011 Dec; 37(12):1970-6.
    View in: PubMed
    Score: 0.122
  55. Increased long-term risk of new-onset diabetes mellitus in white-coat and masked hypertension. J Hypertens. 2009 Aug; 27(8):1672-8.
    View in: PubMed
    Score: 0.104
  56. Cardiac, neuroadrenergic, and portal hemodynamic effects of prolonged aldosterone blockade in postviral child A cirrhosis. Am J Gastroenterol. 2005 May; 100(5):1110-6.
    View in: PubMed
    Score: 0.078
  57. Lifestyle, psychological, socioeconomic and environmental factors and their impact on hypertension during the coronavirus disease 2019 pandemic. J Hypertens. 2021 06 01; 39(6):1077-1089.
    View in: PubMed
    Score: 0.059
  58. Hypertension and COVID-19: Ongoing Controversies. Front Cardiovasc Med. 2021; 8:639222.
    View in: PubMed
    Score: 0.058
  59. Management of supine hypertension in patients with neurogenic orthostatic hypotension: scientific statement of the American Autonomic Society, European Federation of Autonomic Societies, and the European Society of Hypertension. J Hypertens. 2019 08; 37(8):1541-1546.
    View in: PubMed
    Score: 0.052
  60. Isolated systolic hypertension in the young: a position paper endorsed by the European Society of Hypertension. J Hypertens. 2018 06; 36(6):1222-1236.
    View in: PubMed
    Score: 0.048
  61. Consensus statement on the definition of neurogenic supine hypertension in cardiovascular autonomic failure by the American Autonomic Society (AAS) and the European Federation of Autonomic Societies (EFAS) : Endorsed by the European Academy of Neurology (EAN) and the European Society of Hypertension (ESH). Clin Auton Res. 2018 08; 28(4):355-362.
    View in: PubMed
    Score: 0.048
  62. In healthy normotensive subjects age and blood pressure better predict subclinical vascular and cardiac organ damage than atherosclerosis biomarkers. Blood Press. 2018 10; 27(5):262-270.
    View in: PubMed
    Score: 0.048
  63. Determinants of carotid-femoral pulse wave velocity progression in hypertensive patients over a 3.7 years follow-up. Blood Press. 2018 02; 27(1):32-40.
    View in: PubMed
    Score: 0.046
  64. Sympathetic nerve traffic and blood pressure changes after bilateral renal denervation in resistant hypertension: a time-integrated analysis. Nephrol Dial Transplant. 2017 Aug 01; 32(8):1351-1356.
    View in: PubMed
    Score: 0.045
  65. Cancer risk associated with use of metformin and sulfonylurea in type 2 diabetes: a meta-analysis. Oncologist. 2012; 17(6):813-22.
    View in: PubMed
    Score: 0.032
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.